본문 바로가기

Intravenous delivery of a multi-mechanistic cancer-targeted oncolytic poxvirus in humans

문서 유형
연구출판물 · 학술지 논문
등재
Nature IndexSCIEScopus
저널 순위
JCR Q1
저널
NATURE477(7362) · pp.99 · 2011
피인용
Web of Science 471
JCR IF
JCR 2010 36.104
ISSN
0028-0836

저자

  1. Breitbach, Caroline J.제1저자Jennerex Inc., United States
  2. Burke, JamesJennerex Inc., United States
  3. Jonker, DerekOttawa Hospital Research Institute, Canada
  4. Stephenson, JoeCancer Centers of the Carolinas, United States
  5. Haas, Andrew R.University of Pennsylvania Medical Center, United States
  6. Chow, Laura Q. M.Ottawa Hospital Research Institute, Canada
  7. Nieva, JorgeDepartment of Hematology/Oncology, Billings Clinic, United States
  8. 황태호Pusan National University, South Korea
  9. Moon, AnneJennerex Inc., United States
  10. Patt, RichardRadMD, United States
  11. Pelusio, AdinaJennerex Inc., United States
  12. Le Boeuf, FabriceOttawa Hospital Research Institute, Canada
  13. Burns, JoeOttawa Hospital Research Institute, Canada
  14. Evgin, LauraOttawa Hospital Research Institute, Canada
  15. De Silva, NaomiOttawa Hospital Research Institute, Canada
  16. Cvancic, SaraOttawa Hospital Research Institute, Canada
  17. Robertson, TerriJennerex Inc., United States
  18. Je, Ji-EunPusan National University, South Korea
  19. 이연숙Pusan National University, South Korea
  20. Parato, KelleyOttawa Hospital Research Institute, Canada
  21. Diallo, Jean-SimonOttawa Hospital Research Institute, Canada
  22. Fenster, AaronRobarts Research Institute, Canada
  23. Daneshmand, ManijehOttawa Hospital Research Institute, Canada
  24. Bell, John C.Ottawa Hospital Research Institute, Canada
  25. Kirn, David H.교신저자Jennerex Inc., United States

초록

The efficacy and safety of biological molecules in cancer therapy, such as peptides and small interfering RNAs (siRNAs), could be markedly increased if high concentrations could be achieved and amplified selectively in tumour tissues versus normal tissues after intravenous administration. This has not been achievable so far in humans. We hypothesized that a poxvirus, which evolved for blood-borne systemic spread in mammals, could be engineered for cancer-selective replication and used as a vehicle for the intravenous delivery and expression of transgenes in tumours. JX-594 is an oncolytic poxvirus engineered for replication, transgene expression and amplification in cancer cells harbouring activation of the epidermal growth factor receptor (EGFR)/Ras pathway, followed by cell lysis and anticancer immunity(1). Here we show in a clinical trial that JX-594 selectively infects, replicates and expresses transgene products in cancer tissue after intravenous infusion, in a dose-related fashion. Normal tissues were not affected clinically. This platform technology opens up the possibility of multifunctional products that selectively express high concentrations of several complementary therapeutic and imaging molecules in metastatic solid tumours in humans.

키워드

VACCINIA VIRUSGM-CSFIMATINIB MESYLATETHYMIDINE KINASEMEASLES-VIRUSGROWTH-FACTORTHERAPYTUMORSCRITERIAPROGRESS

식별자

WoS UID
000294404300039